The synergy between alkylating agents and ERCC1–XPF inhibitors is p53 dependent

Documenti analoghi

• Fundamental and Clinical Pharmacology of drug repositioning
  di: Lars Petter Jordheim
  Pubblicazione: (2025)
• JAK/STAT inhibitors mitigate sepsis‐associated cerebral and cognitive injury
  di: Mohini Singh Bhadauriya, et al.
  Pubblicazione: (2025)
• Breastfeeding and contrast agents—A critical review and presentation of new aspects
  di: Sina Lemmenmeier, et al.
  Pubblicazione: (2024)
• Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
  di: Pedro H. Reis‐Barbosa, et al.
  Pubblicazione: (2024)
• Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growth
  di: Marwa M. Khalaf, et al.
  Pubblicazione: (2025)